本帖最后由 老马 于 2013-3-13 13:43 编辑 5 T# Y# M7 ~0 l
% ?+ B4 K5 a) P8 ~
健择(吉西他滨)+顺铂+阿瓦斯汀- I5 P% o# m1 f. t2 x+ ^
Gemzar +Cisplatin + Avastin
% R3 f* o, Y5 t9 T) s8 ?3 Hhttp://annonc.oxfordjournals.org/content/21/9/1804.full: z- w k0 C" ~
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
v/ v/ t' B. `& k" }0 S# sPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ! S' A% Z; z r' ?' m+ H
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. _" A: d& d* [0 u9 q7 p
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
4 ^5 [; I3 p8 F% c0 R8 n2 o
华为网盘附件:
4 i, Z) C, e5 U' n% J【华为网盘】ava.JPG
4 Q( v" R1 n' X& x |